Related Experiment Video

Updated: Aug 28, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K

NCAPG2 Maintains Cancer Stemness and Promotes Erlotinib Resistance in Lung Adenocarcinoma

Shiyao Jiang1,2, Jingjing Huang1,2, Hua He1,2

  • 1The Key Laboratory of Model Animal and Stem Cell Biology in Hunan Province, Hunan Normal University, Changsha 410013, China.

Cancers
|September 23, 2022
PubMed

Insights

NCAPG2 is identified as a key gene driving erlotinib resistance and cancer stemness in lung adenocarcinoma (LUAD). This finding offers a potential biomarker and therapeutic target for improving patient prognosis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is used for lung adenocarcinoma (LUAD) but resistance is common.
  • Acquired resistance to erlotinib and the presence of cancer stem cells (CSCs) negatively impact patient outcomes in LUAD.
  • The interplay between erlotinib resistance and CSCs in LUAD pathogenesis remains incompletely understood.

Purpose of the Study:

  • To identify potential biomarkers and elucidate the molecular mechanisms underlying erlotinib resistance and cancer stemness in LUAD.
  • To investigate the role of specific genes in mediating these processes.

Main Methods:

  • Construction of an erlotinib resistance model using data from TCGA, GEO, CCLE, and GDSC databases.
  • Comprehensive bioinformatic analyses to identify key genes.
  • In vitro experiments to validate the function of the identified gene.

Main Results:

  • NCAPG2 was identified as a crucial gene associated with both erlotinib resistance and stemness characteristics in LUAD.
  • Experimental validation confirmed that NCAPG2 promotes stemness and contributes to erlotinib resistance in LUAD cells.

Conclusions:

  • NCAPG2 plays a significant role in maintaining cancer stemness and conferring resistance to erlotinib in LUAD.
  • NCAPG2 represents a potential therapeutic target for overcoming erlotinib resistance and improving treatment efficacy in LUAD.
Keywords:
NCAPG2cancer stem cellserlotinib resistancelung adenocarcinomatumor microenvironment

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.7K

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.8K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K